RBC Bioscience Corporation (TPEX:6848)
Taiwan · Delayed Price · Currency is TWD 16.25
-0.25 (-1.52%)
Feb 11, 2026, 2:07 PM CST
RBC Bioscience Revenue
RBC Bioscience had revenue of 107.70M TWD in the half year ending June 30, 2025, with 21.09% growth. This brings the company's revenue in the last twelve months to 201.85M, up 3.72% year-over-year. In the year 2024, RBC Bioscience had annual revenue of 205.25M with 19.01% growth.
Revenue (ttm)
201.85M
Revenue Growth
+3.72%
P/S Ratio
1.04
Revenue / Employee
3.88M
Employees
52
Market Cap
210.86M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 205.25M | 32.78M | 19.01% |
| Dec 31, 2023 | 172.47M | -1.42M | -0.82% |
| Dec 31, 2022 | 173.89M | -77.29M | -30.77% |
| Dec 31, 2021 | 251.18M | -323.98M | -56.33% |
| Dec 31, 2020 | 575.16M | 413.49M | 255.74% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Taiwan Advance Bio-Pharmaceutical | 371.86M |
| TCI GENE | 324.73M |
| BioLASCO Taiwan | 277.12M |
| NatureWise Biotech & Medicals | 180.29M |
| Feng Chi Biotech | 179.94M |
| Visgeneer | 159.76M |
| Vectorite Biomedical | 67.90M |
| Neith | 39.35M |